Clinical validation is the post-analytical addition of remarks onto a laboratory report aimed at helping the requesting clinician fully interpret the ¢ndings of a test. As such, it is one part of the clinical liaison process with users of the service. This task is usually performed by a suitably quali¢ed member of laboratory sta¡ who is in the unique position of understanding the potential for analytical and pre-analytical errors, and can correlate the results to the patient's clinical status. 1 Until the 1990s, clinical validation of most clinical biochemistry tests was largely unavoidable since the relative unreliability of methods meant this task was an essential step in maintaining overall quality assurance (QA). Computer systems were also not yet at the stage where they could help identify clinically abnormal or analytically incorrect results from a sea of unremarkable reports. In addition, the workload of requests received was at a level where it was feasible for such a labour intensive system to be used.
Analytical issues with assays still exist but as workloads have increased, methods generally become more reliable, and laboratory computers been put to better use, the role of clinical validation has shifted towards predominantly providing interpretative comments on a minority of computer-selected reports.
There is certainly no shortage of anecdotal and more formal evidence that users of the laboratory service generally value the inclusion of these comments. 2, 3 It has also been suggested that such feedback is one of the reasons that countries with these systems in place have reduced demand for testing compared with similarly developed health-care nations who do not. With an increasing number of non-medical sta¡ directly involved in patient decisions and a reduction in speci¢c clinical biochemistry courses in UK medical schools, it seems demand for clinical comments is liable to continue.
However, unlike our radiology colleagues --who provide a similar service with little thought of doing otherwise --being scientists our profession has naturally questioned the degree to which clinical validation helps in patient care, and whether it is a worthwhile (and/or cost-e¡ective) use of highly skilled sta¡. 4 There is also a lack of consensus about the breadth of tests which should be expected to be included in the clinical validation process, and, more worryingly, concerns raised about the quality of advice given. 1 Unfortunately, these questions of bene¢t (or risk) associated with providing comments are not easily answered. Quantifying the positive opinions of users is relatively simple, but determining whether this translates into tangible improvements in patient care has proved far more di⁄cult. 5 There are, of course, additional or alternative ways of helping clinicians with the interpretation of tests. One is having a readily available telephone advice service for users of the laboratory to contact when they feel necessary. However, demonstrating the bene¢t to patients of solely using this approach (or harm when advice has not been sought) is likely to be just as di⁄cult to demonstrate as it is with clinical validation.
So what is the future for clinical validation? Clearly the phrase 'further research needs to be done' is applicable here. Considering the resources already likely to be invested in clinical validation, basic data about which tests and in which laboratories this function applies remains largely unknown, so pursuit of this information needs to be a priority. Given the way in which clinical validation is embedded within UK laboratories, it means that any randomized trials attempting to address its e¡ectiveness would need to examine the e¡ects of removing, rather than introducing such an interpretative service. This means that further research may either need to be performed outside the UK or be limited to 'head-to-head' comparisons between, say, clinical validation with ad hoc telephone advice against a more readily accessible advice service without interpretative comments.
In the meantime, it seems likely that clinical validation will evolve further with enhancements to national information technology (IT), so that service users will be able to link abnormal results to locally or nationally agreed care pathways through best practice guidelines and 'map of medicine' initiatives. 6, 7 Some of these links could undoubtedly be inserted automatically, but it remains to be seen whether the same health-care sta¡ who complain of information overload would prefer a collection of Web addresses to a succinct clinical comment.
There will be no future for clinical validation if the comments provided are potentially harmful to patients.
QA schemes have now been developed to address this need, 8, 9 although questions around who quality assures the QA schemes have arisen. 10 Finally, it would be ironic if the main incentive for the continuation or demise of clinical validation becomes market rather than patient-care driven. If family doctors in the future decide they want to pay more for their tests to use a particular laboratory because it provides interpretative comments, then we will truly have established the value of such a service.
